Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.

Item

http://www.wikidata.org/entity/Q37065849

Q37065849

about

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer Quantification of HER family receptors in breast cancer Therapeutic targeting of cancers with loss of PTEN function.Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Dual HER2 blockade: preclinical and clinical data Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives.Trastuzumab emtansine: mechanisms of action and drug resistance Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapa The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.The Globalization of Cooperative Groups.PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer.Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity."Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment.Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial.Biomarkers of drugs targeting HER-family signalling in cancer.Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer cell proliferation in vitro and in vivo.HER2-positive breast cancer is lost in translation: time for patient-centered research.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.Resistance to Targeted Therapies in Breast Cancer.Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.Pnck overexpression in HER-2 gene-amplified breast cancer causes Trastuzumab resistance through a paradoxical PTEN-mediated process.

P2860

Q26772969-9F2C2234-E735-4B81-A982-4FF830ADC941 Q26785612-12C3A6F1-038E-43AE-BC79-C7ABD888FEC5 Q27015506-DD753CEC-82EF-4E5E-9A00-BEB32FA2DA9E Q27852764-534746B3-5DCB-4A54-AD18-8AB8F44E5FA0 Q28079118-A20FB603-E7E5-45EA-A793-9A2582CB1F85 Q30941327-7FE391B3-1936-48B8-BC91-C1C853758802 Q33587905-13E19038-E984-4E36-9AB6-70E71DC54B26 Q33601653-8B63FAD0-1348-4494-A171-3A710D572F3C Q33738675-79010832-E1B7-4C5D-802B-27EE72B19ED2 Q33759627-CC4ADE1A-FBE5-4539-8038-78A33A979BA5 Q33762003-39234A39-F983-45FF-981A-9762F39724A5 Q34147910-AF02807C-700B-4276-84AB-E2EB7819C4CA Q34296114-90A6D8A8-E505-451C-BF03-30F039E373EB Q34654520-4CAAB058-84DC-4E87-A72B-017D7F4EF616 Q35000243-53156222-2F3E-43AD-BEDA-6F30746F503B Q35102480-CEFAED0D-784F-401B-8148-FF559716E532 Q35419840-7C32A6B3-DFD5-4155-BE7D-5D71716E5970 Q35562967-4AE64E32-807C-4F94-B742-FB7B4A2BBDD1 Q35740160-D833541F-BF19-49FE-9A20-AFCDAF3F10A0 Q35947005-A37FA2AC-860A-4394-8AC1-092D9282700C Q36064912-46C46FD3-72C3-4D9D-AD65-8EEE1EB8A0A9 Q36117367-C46C58EF-751C-4B71-8C49-EC505518533A Q36119749-C2163B29-41A3-450F-8BE6-C28926AC0D41 Q36295269-650C703A-3D12-40DA-8ED5-A6156B9C00CF Q36544757-3269FC42-29D5-4BCE-9123-69FD3E01192A Q36685380-88DEC401-F981-4678-A11A-6B7C5DF0CF0D Q36978609-2C73B43F-36A5-4F7E-832B-ACEF6C71EBEA Q37080378-7F606193-80B5-483B-BAF0-B47E6DD9A786 Q37109643-904E640E-9EF5-4994-9C71-D3F11EE12C7B Q37221249-9B4151E3-5FAA-4418-8370-07BD4EAC9CD7 Q37246798-B0A3AF3C-6ECE-4F66-AE45-C7A8B2A18F6E Q37507467-B6EF1B4D-5335-43F7-A955-7F3F7C51BCDD Q37632118-16121224-0605-491E-8EF3-8F5C039CE09B Q38150774-D7EF71ED-0D81-402C-B0CD-6B33F9E12EE6 Q38382577-6C14809D-49E2-4928-AEA4-51605B7A9179 Q38648765-88142EC0-F8A3-4B30-8194-E5DF26388A54 Q38661390-0603F30C-F71B-4219-B1D0-E9E4E8AA4EF0 Q38748114-BBD7F018-AC34-4F47-BC53-836BB1E266F2 Q38786102-37A2C088-197B-4C9A-99B6-499247D5A7DF Q38899532-8C0D05B2-035D-4D49-B693-DA72FB7F96E0

P2860

Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.

Item

http://www.wikidata.org/entity/Q37065849

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 May 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs